/ /

  • linkedin
  • Increase Font
  • Sharebar

    Anti-VEGF patterns of use for DME may vary in clinical practice

    Injections less frequent, treatment less effective than in registration trials

    Take-home message: Though anti-vascular endothelial growth factor therapy for diabetic macular edema showed impressive results in trials, clinicians have reported less success on their own.


    St. Louis, MO—Anti-vascular endothelial growth factor (VEGF) treatments for diabetic macular edema (DME) have not worked as well in clinical practice as in clinical trials, according to one clinician.

    “Treatment was less effective than in the registration trials, most likely due to the infrequency of the injections,” said Kevin J. Blinder, MD, partner, The Retina Institute, and professor of clinical ophthalmology and visual sciences, Washington University in Saint Louis, MO.

    To examine this phenomenon, Dr. Blinder and his colleagues, in a trial sponsored by Allergan, reviewed the records of 156 patients who had received at least three anti-VEGF injections for DME at 10 sites.

    Study design

    The patients’ mean age was 63.4 years. More than 80% had type II diabetes, and more than 40% had a history of focal laser photocoagulation treatments.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results